Clinical Trials Browser

INDUSTRY × Interventional × taletrectinib × Clear all

NCT07154706 2026-02-11

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04919811 2026-01-07

TRUST-II

Phase 2 Active not recruiting

217 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung